New hope for tough cancers: trial tests Immune-Boosting drug with chemo
NCT ID NCT06849986
Summary
This study is testing whether adding a new immunotherapy drug called tislelizumab to standard chemotherapy works better for people with advanced soft tissue sarcoma. It will enroll 45 adults with specific types of sarcoma that cannot be removed by surgery or have spread. The main goal is to see if this combination is safe and can shrink tumors or stop them from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.